CY1110428T1 - Χρηση της rosuvastatin (zd-4522) στη θεραπευτικη αντιμετωπιση της ετεροζυγωτικης οικογενους υπερχοληστερολαιμιας - Google Patents

Χρηση της rosuvastatin (zd-4522) στη θεραπευτικη αντιμετωπιση της ετεροζυγωτικης οικογενους υπερχοληστερολαιμιας

Info

Publication number
CY1110428T1
CY1110428T1 CY20081100703T CY081100703T CY1110428T1 CY 1110428 T1 CY1110428 T1 CY 1110428T1 CY 20081100703 T CY20081100703 T CY 20081100703T CY 081100703 T CY081100703 T CY 081100703T CY 1110428 T1 CY1110428 T1 CY 1110428T1
Authority
CY
Cyprus
Prior art keywords
hyperotherological
rosuvastatin
surgery
therapeutic treatment
treatment
Prior art date
Application number
CY20081100703T
Other languages
English (en)
Inventor
Ali Raza
Howard Gerard Hutchinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110428(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1110428T1 publication Critical patent/CY1110428T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση δίδει μία μέθοδο για τη θεραπευτική αντιμετώπιση ετεροζυγωτικής οικογενούς υπερχοληστερολαιμίας με χορήγηση της ένωσης (Ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3R,5S)-3,5-διυδροξυεπτ-6-ενοϊκό οξύ ή ενός φαρμακευτικώς ανεκτού άλατος αυτής.
CY20081100703T 2000-11-22 2008-07-07 Χρηση της rosuvastatin (zd-4522) στη θεραπευτικη αντιμετωπιση της ετεροζυγωτικης οικογενους υπερχοληστερολαιμιας CY1110428T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
EP01982623A EP1339409B1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
CY1110428T1 true CY1110428T1 (el) 2015-04-29

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100703T CY1110428T1 (el) 2000-11-22 2008-07-07 Χρηση της rosuvastatin (zd-4522) στη θεραπευτικη αντιμετωπιση της ετεροζυγωτικης οικογενους υπερχοληστερολαιμιας

Country Status (35)

Country Link
US (1) US6858618B2 (el)
EP (1) EP1339409B1 (el)
JP (2) JP5062940B2 (el)
KR (1) KR100815042B1 (el)
CN (1) CN1268339C (el)
AR (1) AR031766A1 (el)
AT (1) ATE394103T1 (el)
AU (2) AU1416502A (el)
BG (1) BG66009B1 (el)
BR (1) BR0115511A (el)
CA (1) CA2429263C (el)
CY (1) CY1110428T1 (el)
CZ (1) CZ301583B6 (el)
DE (1) DE60133921D1 (el)
DK (1) DK1339409T3 (el)
EE (1) EE05507B1 (el)
ES (1) ES2305118T3 (el)
GB (1) GB0028429D0 (el)
HK (1) HK1056691A1 (el)
HU (1) HUP0301380A3 (el)
IL (2) IL155919A0 (el)
IS (1) IS6819A (el)
MX (1) MXPA03004336A (el)
MY (1) MY134902A (el)
NO (1) NO326245B1 (el)
NZ (1) NZ525754A (el)
PL (1) PL365386A1 (el)
PT (1) PT1339409E (el)
RU (1) RU2294744C2 (el)
SI (1) SI1339409T1 (el)
SK (1) SK6212003A3 (el)
TW (1) TWI238720B (el)
UA (1) UA75614C2 (el)
WO (1) WO2002041895A1 (el)
ZA (1) ZA200303636B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
MXPA05011296A (es) * 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
CA2567963A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc. Functional foods comprising flavonoids and tocotrienols and methods thereof
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
MX2007010138A (es) * 2005-02-22 2007-09-27 Teva Pharma Preparacion de rosuvastatina.
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
PL2307435T3 (pl) 2008-07-08 2012-11-30 Gilead Sciences Inc Sole związków inhibitorów HIV
TWI652260B (zh) 2012-09-17 2019-03-01 美商瑪德瑞高製藥公司 用以合成甲狀腺激素類似物及其多形體之方法
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
EP3976805A1 (en) 2019-05-27 2022-04-06 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
US20240307405A1 (en) * 2021-02-01 2024-09-19 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DE60129573T2 (de) * 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Also Published As

Publication number Publication date
CN1630520A (zh) 2005-06-22
MY134902A (en) 2007-12-31
ES2305118T3 (es) 2008-11-01
WO2002041895A1 (en) 2002-05-30
PT1339409E (pt) 2008-07-07
RU2294744C2 (ru) 2007-03-10
GB0028429D0 (en) 2001-01-10
HUP0301380A2 (hu) 2003-10-28
BR0115511A (pt) 2003-12-30
PL365386A1 (en) 2005-01-10
HUP0301380A3 (en) 2007-03-28
EP1339409B1 (en) 2008-05-07
SK6212003A3 (en) 2003-11-04
ZA200303636B (en) 2004-08-12
US6858618B2 (en) 2005-02-22
MXPA03004336A (es) 2003-08-19
CN1268339C (zh) 2006-08-09
BG66009B1 (bg) 2010-10-29
JP2004522714A (ja) 2004-07-29
NO326245B1 (no) 2008-10-27
EE200300239A (et) 2003-08-15
TWI238720B (en) 2005-09-01
AU2002214165B9 (en) 2013-07-04
HK1056691A1 (en) 2004-02-27
DK1339409T3 (da) 2008-09-08
IL155919A0 (en) 2003-12-23
AU1416502A (en) 2002-06-03
AU2002214165B2 (en) 2006-12-14
EP1339409A1 (en) 2003-09-03
KR20030048479A (ko) 2003-06-19
CZ301583B6 (cs) 2010-04-21
JP5062940B2 (ja) 2012-10-31
BG107811A (bg) 2004-03-31
CA2429263C (en) 2009-03-17
CZ20031406A3 (cs) 2003-09-17
NO20032292L (no) 2003-07-17
IS6819A (is) 2003-05-19
JP2010031047A (ja) 2010-02-12
NZ525754A (en) 2004-10-29
NO20032292D0 (no) 2003-05-21
DE60133921D1 (de) 2008-06-19
KR100815042B1 (ko) 2008-03-18
UA75614C2 (uk) 2006-05-15
EE05507B1 (et) 2012-02-15
CA2429263A1 (en) 2002-05-30
SI1339409T1 (sl) 2008-08-31
AR031766A1 (es) 2003-10-01
ATE394103T1 (de) 2008-05-15
US20040072852A1 (en) 2004-04-15
IL155919A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CY1110428T1 (el) Χρηση της rosuvastatin (zd-4522) στη θεραπευτικη αντιμετωπιση της ετεροζυγωτικης οικογενους υπερχοληστερολαιμιας
CY1110992T1 (el) ΣΥΝΔΥΑΣΜΕΝΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΠΕΡΙΕΧΟΥΝ (Ε)-7-[4-(4-ΦΘΟΡΟΦΑΙΝΥΛ)-6-ΙΣΟΠΡΟΠΥΛ-2-[ΜΕΘΥΛ(ΜΕΘΥΛΣΟΥΛΦΟΝΥΛ)ΑΜΙΝΟ]ΠΥΡΙΜΙΔΙΝ-5-ΥΛ](3r,5s)-3,5-ΔΙΥΔΡΟΞΥΕΠΤ-6-ΕΝΟΪΚΟ ΟΞΥ
EE05586B1 (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
CY1107225T1 (el) Κρυσταλλικα αλατα του 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ]-(3r,5s)-3-5-διυδροξυεπτ-6-ενοϊκου οξεος
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
HUP0104828A2 (hu) Kristályos bisz[ (E)-7-[4-(4-fluor-fenil)-6-izopropil-2-[metil-(metilszulfonil)-amino]-pirimidin-5-il]-(3R,5S)-3,5-dihidroxi-6-hepténsav]-kalciumsó, ezt tartalmazó készítmény és eljárás az előállításukra
CY1113894T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη
CY1106402T1 (el) Μεθοδος θepαπειας του συνδρομου tourette
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
MY136382A (en) Use of cholesterol-lowering agent
TH88724B (th) การรักษา
TH88724A (th) การรักษา